👁️ Mechanism and Application of Corneal Cross-Linking (CXL) Devices
Corneal Cross-Linking (CXL) Devices are ophthalmologic instruments used to perform a minimally invasive procedure designed to increase the mechanical strength and stiffness of the cornea, the transparent front part of the eye. This procedure is a vital treatment to halt the progression of corneal ectatic disorders, most notably keratoconus, where the cornea progressively thins and bulges outward.
Mechanism of Action: CXL is a photo-polymerization process mediated by the combined action of a photosensitizing agent (usually Riboflavin, or Vitamin B2) and Ultraviolet A (UVA) light (typically 370 nm).
Riboflavin Instillation: Riboflavin drops are applied topically to the corneal surface. Riboflavin acts as a photosensitizer and a UV filter, protecting the deeper, sensitive structures of the eye (like the endothelium and lens).
UVA Irradiation: The CXL device delivers a controlled beam of UVA light. The UVA light activates the riboflavin, which then produces Reactive Oxygen Species (ROS), primarily singlet oxygen.
Cross-Link Formation: These ROS initiate the formation of new chemical bonds (covalent cross-links) between the collagen fibrils and proteoglycans within the corneal stroma. The creation of these new bonds significantly enhances the biomechanical rigidity of the cornea, making it more resistant to stretching and bulging.
Clinical Applications:
Keratoconus: The primary and most common application, where CXL is used to stop or slow the progression of the cone-shaped deformation.
Post-LASIK Ectasia: Treating the progressive thinning that can occur after certain refractive surgeries.
Infectious Keratitis: Experimental or adjunct use to sterilize the cornea and increase its resistance to enzymatic digestion by pathogens.